Trimunocor is a brand that is dedicated to developing groundbreaking solutions in the fight against neonatal chronic lung disease. Their main focus is on protecting premature neonates from this debilitating condition. With a mission to make a difference in the lives of these vulnerable infants, Trimunocor is at the forefront of developing innovative treatments to combat chronic lung disease in newborns.

As a spin-out from the Medical Research Council and the University of Southampton, Trimunocor brings together cutting-edge research and expertise to create effective solutions. They are committed to staying up to date with the latest developments in the field and are constantly working towards finding new ways to improve the lives of premature neonates. Located in Harpenden, Hertfordshire, Trimunocor is a trusted brand that prioritizes the well-being of these tiny patients.

Their dedication to providing high-quality care and life-changing treatments sets them apart in the field of neonatal chronic lung disease